Headquartered in Dublin (Ireland), DS Biopharma is working on new medicines for medical unmet needs, such as fibrosis. This development of fibrous tissue can affect the lungs, liver or heart.
DS has developed a bioactive lipid technology platform, which includes semi-synthetic fatty acids and has already received an European patent.
These lipids are crucial in the pathways of several conditions including metabolic disorders of the liver and fibrotic disorders.
While there is no known effective way of ‘persuade’ the body to produce more of these lipids, DS has synthesised several of these compounds – which could be delivered topically or orally.